T. Maughan

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

M. Parmar, H. Wasan, G. Middleton, 2011, The Lancet.

BMC Cancer BioMed Central Study protocol

Simon Noble, T. Maughan, Gareth O Griffiths, 2008 .

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

D. Lambrechts, M. D. James, J. Bridgewater, 2011, The Lancet.

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

P. Quirke, J. Cheadle, G. Middleton, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease

V. Salomaa, L. Aaltonen, S. Ripatti, 2016, Human molecular genetics.

Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease

V. Salomaa, D. Kerr, L. Aaltonen, 2016, Human molecular genetics.

FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer

S. Noble, D. Cohen, G. Griffiths, 2009, BMC Cancer.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

D. Lambrechts, M. D. James, J. Bridgewater, 2011, The Lancet.

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

S. Gwyther, S. Richman, J. Wadsley, 2013, The Lancet. Oncology.

Molecular subtype-speci fi c ef fi cacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone

D. Sommeijer, S. Hoorn, F. Elliott, 2023 .